Researchers from Congruence Therapeutics Inc. have described the development of a mouse model of genetic obesity with a clinically relevant, naturally occurring human melanocortin MC4 receptor (MC4R) mutation.

Researchers from Adipo Therapeutics LLC presented data from preclinical studies that aimed to assess the γ-secretase inhibitor ADPO-002 (dibenzazepine) for the treatment of obesity.

Researchers at Harvard Medical School have found that blocking the neuron-released peptide CGRP decreases pain sensitivity and reduces lesion size in endometriosis. Endometriosis is a painful, steroid-dependent inflammatory condition in which tissue similar to that of the endometrial lining grows and establishes outside the uterine mucosa.

Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).

Fractyl Health Inc. has nominated RJVA-002, a GIP/GLP-1 dual agonist, as its first pancreatic gene therapy candidate for obesity.

Endevica Bio Inc. has announced the spin-off of a newly created company, Abisati LLC, to develop an oral melanocortin MC4 receptor agonist, 710GO, as a weight loss therapy.

Previous studies have shown that NETosis, a specialized form of neutrophil-specific cell death, is involved in the pathogenesis of diabetes.